Japan targets 'faster than US FDA' medtech approvals, but reimbursement remains a problem
This article was originally published in SRA
Executive Summary
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent ground breaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, senior vice-president of global strategy and analysis at US medtech industry association AdvaMed.
You may also be interested in...
UK Medtechs Determined To Exploit Digital Health Opportunity Born From The Pandemic
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
UK Device Safety To Be Enhanced By Patient Safety Commissioner
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.
Medtech Has Hope For A Solid Recovery Later In 2021
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: